All In Biotech

Drug Trial Radar · NCT07257978

Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

A Phase II/III Double-blind, Randomised, Placebo-controlled, Crossover Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 1, 2027

Primary completion

Oct 1, 2028

Study completion Oct 1, 2028

Sponsor

Lead sponsor
Fenix Innovation GroupIndustry
Sponsor type
Industry
Collaborators
Neurotech International Limited
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 4 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design. RTT is a devastating rare genetic condition affecting females and involves debilitating physical and intellectual symptoms. NTI164 is an oil which has demonstrated efficacy in reducing symptoms in several paediatric neurological conditions, including RTT, autism spectrum disorder (ASD), and paediatric acute-onset neuropsychicatric syndrome (PANS). A Phase I/II clinical trial of NTI164 in RTT (FENRTT1/NTIRTT1) showed NTI164 is safe in this population and significantly improved overall clinical severity of illness, as well as core RTT symptoms, including anxiety, mental alertness, communication skills, socialisation/eye contact, and attentiveness. The FENRTT2 study will investigate NTI164 in a larger number of patients, and compare NTI164 to a placebo control. Research tests on patient blood will also be included to further investigate how NTI164 works in the body.

Conditions

  • RETT Syndrome With Proven MECP2 Mutation
  • Rett Syndrome

Interventions

  • NTI164Drug

    NTI164 is a full-spectrum medicinal cannabis plant extract with \<0.3% THC.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rett Syndrome Behaviour Questionnaire (RSBQ)Time frame: Baseline, Week 12, and Week 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Monash Health

    Clayton, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.